AKT1 and breast cancer: Interestingly, phase II trials evaluating the addition of AKT inhibitors to first-line Paclitaxel for triple-negative BC consistently reported an association between PI3K pathway deregulation (including PTEN alterations) and response to AKT inhibitors treatment both in advanced and early setting.